Method for screening nucleic acid catalysts

Details Method for screening nucleic acid catalysts Method for screening nucleic acid catalysts

1998-06-09

2001-08-28

Fredman, Jeffrey (Department: 1655)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C536S024500, C536S023100, C536S024300, C435S006120, C435S252300, C435S320100

Reexamination Certificate

active

06280936

ABSTRACT:

BACKGROUND OF THE INVENTION
This invention relates to nucleic acid molecules with catalytic activity and derivatives thereof.
The following is a brief description of catalytic acid molecules. This summary is not meant to be complete but is provided only for understanding of the invention that follows. This summary is not an admission that all of the work described below is prior art to the claimed invention.
Catalytic nucleic acid molecules (ribozymes) are nuclei acid molecules capable of catalyzing one or more of a variety of reactions, including the ability to repeatedly cleave other separate nucleic acid molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be used, for example, to target virtually any RNA transcript (Zaug et al., 324,
Nature
429 1986; Cech 260 JAMA 3030, 1988; and Jefferies et al., 17 Nucleic Acids Research 1371, 1989). Any nucleotide base-comprising molecule having the ability to repeatedly act on one or more types of molecules, including but not limited to enzymatic nucleic acid molecules. By way of example but not limitation, such molecules, peptides, or other polymers, and those that are able to cause the polymerization of such nucleic acids and other polymers. Specifically, such molecules include ribozymes, DNAzymes, external guide sequences and the like. It is expected that such molecules will also include modified nucleotides compared to standard nucleotides found in DNA and RNA.
Because of their sequence-specificity, trans-leaving enzymatic nucleic acid molecules show promise as therapeutic agents for human disease (Usman & McSwiggen, 1995
Ann. Rep. Med. Chem.
30, 285-294; Christoffersen and Marr, 1995
J. Med. Chem.
38, 2023-2037). Enzymatic nucleic acid molecules can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the mRNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited.
There are at least seven basic varieties of naturally-occurring enzymatic RNAs. Each can catalyze the hydrolysis of RNA phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.
In addition, several in vitro selection (evolution) strategies (Orgel, 1979,
Proc. R. Soc.
London, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages, (Joyce, 1989,
Gene,
82, 83-87; Beaudry at al., 1992,
Science
257, 635-641; Joyce, 1992,
Scientific American
267, 90-97; Breaker et al., 1994, TIBTECH 12, 268; Bartel et al.,1993,
Science
261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al, 1995,
FASEB J.,
9, 1183; Breaker, 1996,
Curr. Op. Biotech.,
7, 442; Breaker, 1997,
Nature Biotech.
15, 427).
There are several reports that describe the use of a variety of in vitro and in vivo selection strategies to study structure and function of catalytic nucleic acid molecules (Campbell et al., 1995, RNA 1, 598; Joyce 1989,
Gene,
82,83; Lieber at al., 1995,
Mol Cell Biol.
15, 540; Lieber et al., International PCT Publication No. WO 96/01314; Szostak 1988, in
Redesigning the Molecules of Life,
Ed. S. A. Benner, pp 87, Springer-Verlag, Germany; Kramer et al., U.S. Pat. No. 5,616,459; Joyce, U.S. Pat. No. 5,595,873; Szostak et al., U.S. Pat. No. 5,631,146).
The enzymatic nature of a ribozyme is advantageous over other technologies, since the effective concentration of ribozyme necessary to effect a therapeutic treatment is generally lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme (enzymatic nucleic acid) molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base-pairing. Thus, it is thought that the specificity of action of a ribozyme is greater than that of antisense oligonucleotide binding the same RNA site.
The development of ribozymes that are optimal for catalytic activity would contribute significantly to any strategy that employs RNA-cleaving ribozymes for the purpose of regulating gene expression. The hammerhead ribozyme functions with a catalytic rate (k
cat
) of ~1 min
−1
in the presence of saturating (10 mM) concentrations of Mg
2+
cofactor. However, the rate for this ribozyme in Mg
2+
concentrations that are closer to those found inside cells (0.5-2 mM) can be 10- to 100-fold slower. In contrast, the RNase P holoenzyme can catalyze pre-tRNA cleavage with a k
cat
of ~30 min
−1
under optimal assay conditions. An artificial ‘RNA ligase’ ribozyme (Bartel et al., supra) has been shown to catalyze the corresponding self-modification reaction with a rate of ~100 min
−1
. In addition, it is known that certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min
−1
. Finally, replacement of a specific residue within the catalytic core of the hammerhead with certain nucleotide analogues gives modified ribozymes that show as much as a 10-fold improvement in catalytic rate. These findings demonstrate that ribozymes can promote chemical transformations with catalytic rates that are significantly greater than those displayed in vitro by most natural self-cleaving ribozymes. It is then possible that the structures of certain self-cleaving ribozymes may not be optimized to give maximal catalytic activity, or that entirely new RNA motifs could be made that display significantly faster rates for RNA phosphoester cleavage.
An extensive array of site-directed mutagenesis studies have been conducted with ribozymes such as the hammerhead, hairpin, hepatitis delta virus, group I, group II and others, to probe relationships between nucleotide sequence, chemical composition and catalytic activity. These systematic studies have made clear that most nucleotides in the conserved core of these ribozymes cannot be mutated without significant loss of catalytic activity. In contrast, a combinatorial strategy that simultaneously screens a large pool of mutagenized ribozymes for RNAs that retain catalytic activity could be used more efficiently to define immutable sequences and to identify new ribozyme variants.
Although in vitro selection experiments have been reported with the hammerhead ribozyme (Nakamaye & Eckstein, 1994,
Biochemistry
33, 1271; Long & Uhlenbeck, 1994,
Proc. Natl. Acad. Sci.,
91, 6977; Ishizaka et al., 1995, BBRC 214, 403; Vaish et al., 1997,
Biochemistry,
36, 6495) and Hairpin ribozyme (Berzal et al., 1993,
EMBO, J.,
12, 2567) none of these efforts have successfully screened for all possible combi

Affiliated with

Also associated with

Rating

Method for screening nucleic acid catalysts does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for screening nucleic acid catalysts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening nucleic acid catalysts will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2471163